Moderna begins dosing in phase 3 trial of influenza vaccine mRNA-1010
Maddie Meyer/Getty Images News


Moderna (NASDAQ:MRNA) said the first participants were dosed in a phase 3 trial of its seasonal influenza vaccine mRNA-1010.
The Cambridge, Mass.-based company said in a June 7 release that the trial is expected to enroll ~6K adults in southern hemisphere countries and will evaluate the safety and immunological non-inferiority of mRNA-1010 to a licensed seasonal influenza vaccine in adults 18 years and older.

Moderna added that mRNA-1010 is one of several influenza vaccine candidates being developed in its respiratory portfolio.
"With the start of dosing for its mRNA-1010 program, Moderna now has four programs in late stage Phase 3 studies, including its SARS-CoV-2 booster, RSV, seasonal flu and CMV vaccine candidates. Beginning in the fall of 2022, the Company's Phase 3 pipeline could lead to three respiratory commercial launches over the next two to three years," said Moderna CEO StÃ©phane Bancel.
The four programs in phase 3 trials are for Omicron-containing bivalent COVID booster, influenza, RSV and CMV.